Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 43, Issue 5, Pages 524-531Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyt034
Keywords
cetuximab; chemotherapy; head and neck; squamous cell carcinoma; Phase II trial
Categories
Funding
- Merck KGaA
- Merck Serono Co, Ltd, Tokyo, Japan
- Merck KGaA, Darmstadt, Germany
- Bayer
- Taiho
- Daiichi-Sankyo
- ImClone
- Takeda
- Merck Serono
Ask authors/readers for more resources
To assess the efficacy and safety of cetuximab in combination with cisplatin and 5-fluorouracil for first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. In this open-label, single-arm, multicenter, Phase II study conducted in Japan, patients with confirmed recurrent and/or metastatic squamous cell carcinoma of the head and neck received weekly cetuximab (week 1, 400 mg/m(2); subsequent weeks, 250 mg/m(2)) plus a maximum of six three-weekly cycles of cisplatin (100 mg/m(2), day 1) and 5-fluorouracil (1000 mg/m(2)/day, 24-h infusion, days 14). The primary endpoint was the best overall response assessed by an independent review committee according to the modified World Health Organization criteria. In total, 33 patients received treatment. The most frequent primary tumor site was the hypopharynx (42), and most patients had metastatic disease (85). The best overall response rate as assessed by the independent review committee was 36 (95 confidence interval: 20, 55) and was significantly greater (P 0.002) than the protocol-specified threshold of 15 at the one-sided 5 level. The disease control rate was 88. The median progression-free survival and overall survival were 4.1 and 14.1 months, respectively. There were no unexpected safety concerns. Grade 3 or 4 adverse events were experienced by nearly all patients (32, 97). No adverse events were fatal. The demonstrated efficacy and safety of cetuximab in combination with cisplatin and 5-fluorouracil for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck justify the further use of this combination treatment in this patient population (ClinicalTrials.gov number, NCT00971932).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available